Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 271

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 271
---
, stating that as of December 1, 2023, we had an overdue balance for services
completed under certain proposals by and between the Company, Cambrex High Point, Inc. and Avista Pharma Solutions, Inc. in the aggregate
amount of $492,723.23. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement
with an accredited investor, in the amount of $200,013, which effectively resolved the creditor claim.

Clinilabs, Inc.

On
August 21, 2024, the Company received a letter from Dunn Lambert LLC, the law firm representing Clinilabs, stating that a complaint had
been filed in the Superior Court of New Jersey. The complaint concerns three unpaid invoices totaling $886,412.46, plus interest at a
rate of 6%. On June 1, 2023, Clinilabs entered into a start-up agreement with us. On December 4, 2023, we received five credit notes
and two invoices from Clinilabs pursuant to services performed by Clinilabs under the start-up agreement. Clinilabs demanded $793,112.46
from us for unpaid service fees. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase
agreement with an accredited investor, in consideration of $500,222.91 and 49,475 common shares equal in value to $279,299.90, which
effectively resolved the creditor claim.

CoreRX, Inc.

On
December 11, 2023, we received a notice alleging several causes of action, including a failure to remit payment for services rendered
by CoreRX. On December 11, 2023, we and CoreRX agreed to a structured payment plan in which we agreed to pay CoreRX a total amount of
$1,007,700.50. On October 10, 2024, the Company successfully settled the outstanding claim through a debt purchase agreement with an
accredited investor, in the amount of $511,835, which effectively resolved the creditor claim.

Université
de Lausanne

On August 27, 2024,
the Company received correspondence from Université de Lausanne, initiating the official “audience de conciliation”
procedure, overseen by the ordinary civil court in Lausanne. The hearing was scheduled for October 9, 2024, at the Tribunal d’arr